Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 6/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3292106 | 0.82 | KDM4C (0.57) | KDM4CSMN1; SMN2TSHRHSD17B10MEN1 | |
| SCHEMBL3473479 | 0.77 | TSHR (0.49) | KDM4CSMN1; SMN2GLAMAPTPDE4A | |
| SCHEMBL1546096 | 0.75 | MAPT (0.49) | SMN1; SMN2GLAMAPTPDE4AADORA2A | |
| SCHEMBL4467734 | 0.73 | TSHR (0.43) | SMN1; SMN2GLAMAPTPDE4AADORA2A | |
| SCHEMBL31268559 | 0.73 | KDM4C (0.45) | KDM4CSMN1; SMN2ADORA2ATSHRHSD17B10 | |
| SCHEMBL9765877 | 0.72 | SMN1; SMN2 (0.42) | SMN1; SMN2GLAMAPTPDE4AADORA2A | |
| SCHEMBL3297433 | 0.71 | KMT2A (0.54) | SMN1; SMN2GLAMAPTPDE4AADORA2A | |
| SCHEMBL3294722 | 0.71 | SMN1; SMN2 (0.61) | KDM4CSMN1; SMN2HSD17B10MEN1KMT2A | |
| SCHEMBL31268552 | 0.71 | KDM4C (0.43) | KDM4CSMN1; SMN2MAPTADORA2AHSD17B10 | |
| SCHEMBL31268548 | 0.70 | KDM4C (0.42) | KDM4CSMN1; SMN2HSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737144-B2 | Pyrimido[5,4-e][1,2,4]triazine-5-7-diones, processes for preparing them and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-15 | — | — | US | disclosed |
| US-7737144-B2 | Pyrimido[5,4-e][1,2,4]triazine-5-7-diones, processes for preparing them and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-15 | — | — | US | disclosed |
| EP-1587806-B1 | PYRIMIDO 5,4-E 1,2,4 TRIAZINE-5,7-DIONES, METHODS FOR PRODUCING THE SAME AND THEIR USE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-11-12 | — | — | EP | disclosed |
| EP-1587806-B1 | PYRIMIDO 5,4-E 1,2,4 TRIAZINE-5,7-DIONES, METHODS FOR PRODUCING THE SAME AND THEIR USE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-11-12 | — | — | EP | disclosed |
| US-20080032984-A1 | Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-07 | — | — | US | disclosed |
| US-20080032984-A1 | Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-07 | — | — | US | disclosed |
| EP-1587806-A1 | PYRIMIDO 5,4-E] 1,2,4]TRIAZINE-5,7-DIONES, METHODS FOR PRODUCING THE SAME AND THEIR USE | Aventis Pharma Deutschland GmbH (DE) | 2005-10-26 | — | — | EP | disclosed |
| WO-2004065387-A1 | PYRIMIDO[5,4-E][1,2,4]TRIAZINE-5,7-DIONES, METHODS FOR PRODUCING THE SAME AND THEIR USE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032984-A1 | Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use | CYP3A5, DPP4, DHPS | KDM4C 1928/4885SMN1; SMN2 2952/4885GLA 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.